title: The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma.
abstract: The overall survival with follicular lymphoma has not significantly changed over the last few decades, and there is no universal agreement as to the optimal first-line or subsequent therapy. High-dose chemotherapy with autologous hematopoietic cell transplantation (HCT) confers high response rates and improved progression-free survival in advanced-stage disease, and more recent data indicate a positive effect on overall survival. Initial results with myeloablative allogeneic HCT unequivocally demonstrated a reduction in relapse/progression compared with autologous HCT, but it is associated with prohibitive nonrelapse mortality. Nonmyeloablative or reduced-intensity regimens have substantially reduced up-front toxicity, and preliminary data seem highly encouraging with regard to efficacy. Novel strategies include the use of rituximab for in vivo purging and maintenance therapy. The incorporation of radioimmunoconjugates into conditioning regimens to deliver targeted radiotherapy also appears promising. This review summarizes current and new developments regarding the role of HCT for patients with follicular lymphoma.
authors.affiliation: Division of Blood and Marrow Transplantation, Stanford University Medical Center, CA 94305, USA. glaport@stanford.edu
authors.forename: Ginna G
authors.initials: GG
authors.lastname: Laport
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000401:mortality / Q000628:therapy*; D000069283:Rituximab; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000069283:Rituximab